cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2017-6-133-138cardiovascular-725Research ArticleОБЗОРЫREVIEWSИЗУЧЕНИЕ ДОЛГОЖИТЕЛЬСТВА: СОВРЕМЕННЫЙ СТАТУС ПРОБЛЕМЫ И ПЕРСПЕКТИВЫ. Часть 2THE STUDY OF LONGEVITY: RECENT UPDATES AND FURTHER DIRECTION. PART 2КотовскаяЮ. В.KotovskayaYu. V.

Доктор медицинских наук, профессор, зав. кафедрой кардиологии и персонифицированной медицины ФПК МР МИ, РУДН; руководитель лаборатории сердечно-сосудистого старения ОСП “Российский геронтологический научно-клинический центр”

kotovskaya@bk.ruТкачеваО. Н.TkachevaО. N.

Доктор медицинских наук, профессор, директор, ОСП “Российский геронтологический научно-клинический центр”

РунихинаН. К.RunikhinaN. К.

Доктор медицинских наук, заместитель директора, ОСП “Российский геронтологический научно-клинический центр”

КаштановаД. А.KashtanovaD. A.

Аспирант отдела изучения процессов старения и профилактики возраст-ассоциированных заболеваний, ОСП “Российский геронтологический научно-клинический центр”;  м.н.с. лаборатории биологии старения и биоинформатики, Государственный научно- исследовательский центр профилактической медицины

БойцовС. А.BoytsovS. A.

Доктор медицинских наук, профессор, чл.-корр. РАН, директор

ФГАОУ ВО “Российский университет дружбы народов” Министерства образования и науки Российской Федерации; ФГБОУ ВО “Российский научно-исследовательский медицинский университет им. Н.И. Пирогова” Министерства здравоохранения Российской ФедерацииPeoples’ Friendship University of Russia; N. I. Pirogov Russian National Research Medical University— SD “Russian Gerontological Scientific-Clinical Center”ФГБОУ ВО “Российский научно-исследовательский медицинский университет им. Н.И. Пирогова” Министерства здравоохранения Российской ФедерацииN. I. Pirogov Russian National Research Medical University— SD “Russian Gerontological Scientific-Clinical Center”ФГБОУ ВО “Российский научно-исследовательский медицинский университет им. Н.И. Пирогова” Министерства здравоохранения Российской Федерации ; ФГБУ “Государственный научно- исследовательский центр профилактической медицины” Министерства здравоохранения Российской ФедерацииN. I. Pirogov Russian National Research Medical University— SD “Russian Gerontological Scientific-Clinical Center”; Russian Cardiological Research-and-Production Complex of the Ministry of HealthФГБУ “Государственный научно- исследовательский центр профилактической медицины” Министерства здравоохранения Российской ФедерацииRussian Cardiological Research-and-Production Complex of the Ministry of Health201720122017166133138Copyright © Котовская Ю.В., Ткачева О.Н., Рунихина Н.К., Каштанова Д.А., Бойцов С.А., 20172017Котовская Ю.В., Ткачева О.Н., Рунихина Н.К., Каштанова Д.А., Бойцов С.А.Kotovskaya Y.V., Tkacheva О.N., Runikhina N.К., Kashtanova D.A., Boytsov S.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/725

Несмотря на глобальные демографические тенденции увеличения продолжительности жизни, долгожительство и сверхдолгожительство остаются во многом недостаточно изученной и понятой популяцией. Необходимы широкомасштабные исследования для понимания того, что значит дожить до 100-летнего возраста. Большое количество исследований было посвящено предикторам долгожительства, поиску путей старения, которые могли бы стать терапевтическими мишенями с целью не только собственно продления жизни, но и обеспечения ее качества, оказания медико-социальной гериатрической помощи. Программа “100-летний гражданин”, проводимая ведущими научными коллективами РФ, направлена на получение медицинской, научной и социальной информации, уникальной для страны.

Regardless the global demographic tendencies of life duration increase, longevity and super longevity remain quite understudied and non-fully understood population. Broader studies needed to understand, what it means to live by 100-year old. Lots of studies are about the longevity predictors and ways of ageing, that could be therapeutical targets not simply for life duration, but life quality as well, and medical-social geriatrics. The program “A Centenarian”, being conducted by leading scientific groups inRussia, is approaching a country unique medical, scientific and social data. 

долгожительствостарениепрограммы “100-летний гражданин”комплексная гериатрическая оценкаlongevityageinga centenariancomplex geriatrician assessmentReferencesVergani C, Lucchi T, Caloni M, et al. I405V polymorphism of the cholesteryl ester transfer protein (CETP) gene in young and very old people. Arch Gerontol Geriatr 2006; 43(2): 213-21. DOI: 10.1016/j.archger.2005.10.008Vergani C, Lucchi T, Caloni M, et al. I405V polymorphism of the cholesteryl ester transfer protein (CETP) gene in young and very old people. Arch Gerontol Geriatr 2006; 43(2): 213-21. DOI: 10.1016/j.archger.2005.10.008Sanders AE, Wang C, Katz M, et al. Association of a functional polymorphism in the cholesteryl ester transfer protein (CETP) gene with memory decline and incidence of dementia. JAMA 2010; 303(2): 150-8. DOI: 10.1001/jama.2009.1988Sanders AE, Wang C, Katz M, et al. Association of a functional polymorphism in the cholesteryl ester transfer protein (CETP) gene with memory decline and incidence of dementia. JAMA 2010; 303(2): 150-8. DOI: 10.1001/jama.2009.1988Atzmon G, Rincon M, Schechter CB, et al. Lipoprotein genotype and conserved pathway for exceptional longevity in humans. PLoS Biol 2006; 4(4): e113. DOI: 10.1371/journal.pbio.0040113Atzmon G, Rincon M, Schechter CB, et al. Lipoprotein genotype and conserved pathway for exceptional longevity in humans. PLoS Biol 2006; 4(4): e113. DOI: 10.1371/journal.pbio.0040113Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 2008; 322(5908): 1702-5. DOI: 10.1126/science.1161524 5. Atzmon G, Pollin TI, Crandall J, et al. Adiponectin levels and genotype: a potential regulator of life span in humans. J Gerontol A Biol Sci Med Sci 2008; 63(5): 447-53.Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 2008; 322(5908): 1702-5. DOI: 10.1126/science.1161524 5. Atzmon G, Pollin TI, Crandall J, et al. Adiponectin levels and genotype: a potential regulator of life span in humans. J Gerontol A Biol Sci Med Sci 2008; 63(5): 447-53.Atzmon G, Barzilai N, Surks MI, et al. Genetic predisposition to elevated serum thyrotropin is associated with exceptional longevity. J Clin Endocrinol Metab 2009; 94(12): 4768-75. DOI: 10.1210/jc.2009-0808Atzmon G, Barzilai N, Surks MI, et al. Genetic predisposition to elevated serum thyrotropin is associated with exceptional longevity. J Clin Endocrinol Metab 2009; 94(12): 4768-75. DOI: 10.1210/jc.2009-0808Atzmon G, Barzilai N, Hollowell JG, et al. Extreme longevity is associated with increased serum thyrotropin. J Clin Endocrinol Metab 2009; 94(4): 1251-4. DOI: 10.1210/jc.2008-325Atzmon G, Barzilai N, Hollowell JG, et al. Extreme longevity is associated with increased serum thyrotropin. J Clin Endocrinol Metab 2009; 94(4): 1251-4. DOI: 10.1210/jc.2008-325Rozing MP, Houwing-Duistermaat JJ, Slagboom PE, et al. Familial longevity is associated with decreased thyroid function. J Clin Endocrinol Metab 2010; 95(11): 4979-84. DOI: 10.1210/jc.2010-0875Rozing MP, Houwing-Duistermaat JJ, Slagboom PE, et al. Familial longevity is associated with decreased thyroid function. J Clin Endocrinol Metab 2010; 95(11): 4979-84. DOI: 10.1210/jc.2010-0875Tabatabaie V, Surks MI. The aging thyroid. Curr Opin Endocrinol Diabetes Obes 2013; 20(5): 455-9. DOI: 10.1097/01.med.0000433055.99570.52Tabatabaie V, Surks MI. The aging thyroid. Curr Opin Endocrinol Diabetes Obes 2013; 20(5): 455-9. DOI: 10.1097/01.med.0000433055.99570.52Brown-Borg HM, Borg KE, Meliska CJ, et al. Dwarf mice and the ageing process. Nature 1996; 384(6604): 33. DOI: 10.1038/384033a0Brown-Borg HM, Borg KE, Meliska CJ, et al. Dwarf mice and the ageing process. Nature 1996; 384(6604): 33. DOI: 10.1038/384033a0Samaras TT, Elrick H. Height, body size, and longevity: is smaller better for the human body? West J Med 2002; 176(3): 206-8.Samaras TT, Elrick H. Height, body size, and longevity: is smaller better for the human body? West J Med 2002; 176(3): 206-8.Kenyon C, Chang J, Gensch E, et al. A C. elegans mutant that lives twice as long as wild type. Nature 1993; 366(6454): 461-4. DOI: 10.1038/366461a0Kenyon C, Chang J, Gensch E, et al. A C. elegans mutant that lives twice as long as wild type. Nature 1993; 366(6454): 461-4. DOI: 10.1038/366461a0Sandhu MS, Heald AH, Gibson JM, et al. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet 2002; 359(9319): 1740-5. DOI: 10.1016/S0140-6736(02)08655-5Sandhu MS, Heald AH, Gibson JM, et al. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet 2002; 359(9319): 1740-5. DOI: 10.1016/S0140-6736(02)08655-5Burgers AM, Biermasz NR, Schoones JW, et al. Meta-analysis and dose-response metaregression: circulating insulin-like growth factor I (IGF-I) and mortality. J Clin Endocrinol Metab 2011; 96(9): 2912-20. DOI: 10.1210/jc.2011-1377Burgers AM, Biermasz NR, Schoones JW, et al. Meta-analysis and dose-response metaregression: circulating insulin-like growth factor I (IGF-I) and mortality. J Clin Endocrinol Metab 2011; 96(9): 2912-20. DOI: 10.1210/jc.2011-1377Pawlikowska L, Hu D, Huntsman S, et al. Association of common genetic variation in the insulin/IGF1 signaling pathway with human longevity. Aging Cell 2009; 8(4): 460- 72. DOI: 10.1111/j.1474-9726.2009.00493.xPawlikowska L, Hu D, Huntsman S, et al. Association of common genetic variation in the insulin/IGF1 signaling pathway with human longevity. Aging Cell 2009; 8(4): 460- 72. DOI: 10.1111/j.1474-9726.2009.00493.xSuh Y, Atzmon G, Cho MO, et al. Functionally significant insulin-like growth factor I receptor mutations in centenarians. Proc Natl Acad Sci U S A 2008; 105(9): 3438-42. DOI: 10.1073/pnas.0705467105Suh Y, Atzmon G, Cho MO, et al. Functionally significant insulin-like growth factor I receptor mutations in centenarians. Proc Natl Acad Sci U S A 2008; 105(9): 3438-42. DOI: 10.1073/pnas.0705467105Tazearslan C, Huang J, Barzilai N, et al. Impaired IGF1R signaling in cells expressing longevity-associated human IGF1R alleles. Aging Cell 2011; 10(3): 551-4. DOI: 10.1111/j.1474-9726.2011.00697.хTazearslan C, Huang J, Barzilai N, et al. Impaired IGF1R signaling in cells expressing longevity-associated human IGF1R alleles. Aging Cell 2011; 10(3): 551-4. DOI: 10.1111/j.1474-9726.2011.00697.хGuevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med 2011; 3(70): 70ra13. DOI: 10.1126/scitranslmed.3001845Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med 2011; 3(70): 70ra13. DOI: 10.1126/scitranslmed.3001845Milman S, Atzmon G, Huffman DM, et al. Low insulin-like growth factor-1 level predicts survival in humans with exceptional longevity. Aging Cell 2014; 13(4): 769- 71. DOI: 10.1111/acel.12213Milman S, Atzmon G, Huffman DM, et al. Low insulin-like growth factor-1 level predicts survival in humans with exceptional longevity. Aging Cell 2014; 13(4): 769- 71. DOI: 10.1111/acel.12213Atzmon G, Cho M, Cawthon RM, et al. Evolution in health and medicine Sackler colloquium: Genetic variation in human telomerase is associated with telomere length in Ashkenazi centenarians. Proc Natl Acad Sci U S A 2010; 107 Suppl 1: 1710-7. DOI: 10.1073/pnas.0906191106Atzmon G, Cho M, Cawthon RM, et al. Evolution in health and medicine Sackler colloquium: Genetic variation in human telomerase is associated with telomere length in Ashkenazi centenarians. Proc Natl Acad Sci U S A 2010; 107 Suppl 1: 1710-7. DOI: 10.1073/pnas.0906191106Han J, Atzmon G, Barzilai N, et al. Genetic variation in Sirtuin 1 (SIRT1) is associated with lipid profiles but not with longevity in Ashkenazi Jews. Transl Res 2015; 165(4): 480-1. DOI: 10.1016/j.trsl.2014.09.008Han J, Atzmon G, Barzilai N, et al. Genetic variation in Sirtuin 1 (SIRT1) is associated with lipid profiles but not with longevity in Ashkenazi Jews. Transl Res 2015; 165(4): 480-1. DOI: 10.1016/j.trsl.2014.09.008Gombar S, Jung HJ, Dong F, et al. Comprehensive microRNA profiling in B-cells of human centenarians by massively parallel sequencing. BMC Genomics 2012; 13: 353. DOI: 10.1186/1471-2164-13-353Gombar S, Jung HJ, Dong F, et al. Comprehensive microRNA profiling in B-cells of human centenarians by massively parallel sequencing. BMC Genomics 2012; 13: 353. DOI: 10.1186/1471-2164-13-353Barzilai N, Atzmon G, Schechter C, et al. Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA 2003; 290(15): 2030-40. DOI: 10.1001/ jama.290.15.2030Barzilai N, Atzmon G, Schechter C, et al. Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA 2003; 290(15): 2030-40. DOI: 10.1001/ jama.290.15.2030McLain JH, Alsterda AJ, Arora RR. Cholesteryl Ester Transfer Protein Inhibitors: Trials and Tribulations. J Cardiovasc Pharmacol Ther 2016 DOI: 10.1177/1074248416662349McLain JH, Alsterda AJ, Arora RR. Cholesteryl Ester Transfer Protein Inhibitors: Trials and Tribulations. J Cardiovasc Pharmacol Ther 2016 DOI: 10.1177/1074248416662349van der Tuin SJ, Kuhnast S, Berbee JF, et al. Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9. J Lipid Res 2015; 56(11): 2085-93. DOI: 10.1194/jlr.M057794van der Tuin SJ, Kuhnast S, Berbee JF, et al. Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9. J Lipid Res 2015; 56(11): 2085-93. DOI: 10.1194/jlr.M057794Roddy TP, McLaren DG, Chen Y, et al. Effects of anacetrapib on plasma lipids, apolipoproteins and PCSK9 in healthy, lean rhesus macaques. Eur J Pharmacol 2014; 740: 410-6. DOI: 10.1016/j.ejphar.2014.04.015Roddy TP, McLaren DG, Chen Y, et al. Effects of anacetrapib on plasma lipids, apolipoproteins and PCSK9 in healthy, lean rhesus macaques. Eur J Pharmacol 2014; 740: 410-6. DOI: 10.1016/j.ejphar.2014.04.015Girona J, Ibarretxe D, Plana N, et al. Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases. Cardiovasc Diabetol 2016; 15(1): 107. DOI: 10.1186/s12933-016-0428-zGirona J, Ibarretxe D, Plana N, et al. Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases. Cardiovasc Diabetol 2016; 15(1): 107. DOI: 10.1186/s12933-016-0428-zLee RG, Crosby J, Baker BF, et al. Antisense technology: an emerging platform for cardiovascular disease therapeutics. J Cardiovasc Transl Res 2013; 6(6): 969-80. DOI: 10.1007/s12265-013-9495-7Lee RG, Crosby J, Baker BF, et al. Antisense technology: an emerging platform for cardiovascular disease therapeutics. J Cardiovasc Transl Res 2013; 6(6): 969-80. DOI: 10.1007/s12265-013-9495-7Milman S, Barzilai N. Dissecting the Mechanisms Underlying Unusually Successful Human Health Span and Life Span. Cold Spring Harb Perspect Med 2015; 6(1): a025098. DOI: 10.1101/cshperspect.a025098Milman S, Barzilai N. Dissecting the Mechanisms Underlying Unusually Successful Human Health Span and Life Span. Cold Spring Harb Perspect Med 2015; 6(1): a025098. DOI: 10.1101/cshperspect.a025098Mannick JB, Del Giudice G, Lattanzi M, et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med 2014; 6(268): 268ra179. DOI: 10.1126/ scitranslmed.3009892Mannick JB, Del Giudice G, Lattanzi M, et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med 2014; 6(268): 268ra179. DOI: 10.1126/ scitranslmed.3009892Anisimov VN, Egormin PA, Piskunova TS, et al. Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell Cycle 2010; 9(1): 188-97. DOI: 10.4161/ cc.9.1.10407Anisimov VN, Egormin PA, Piskunova TS, et al. Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell Cycle 2010; 9(1): 188-97. DOI: 10.4161/ cc.9.1.10407Anisimov VN, Berstein LM, Popovich IG, et al. If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice. Aging (Albany NY) 2011; 3(2): 148-57. DOI: 10.18632/aging.100273Anisimov VN, Berstein LM, Popovich IG, et al. If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice. Aging (Albany NY) 2011; 3(2): 148-57. DOI: 10.18632/aging.100273Martin-Montalvo A, Mercken EM, Mitchell SJ, et al. Metformin improves healthspan and lifespan in mice. Nat Commun 2013; 4: 2192. DOI: 10.1038/ncomms3192 34. Cabreiro F, Au C, Leung KY, et al. Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism. Cell 2013; 153(1): 228-39. DOI: 10.1016/j.cell.2013.02.035Martin-Montalvo A, Mercken EM, Mitchell SJ, et al. Metformin improves healthspan and lifespan in mice. Nat Commun 2013; 4: 2192. DOI: 10.1038/ncomms3192 34. Cabreiro F, Au C, Leung KY, et al. Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism. Cell 2013; 153(1): 228-39. DOI: 10.1016/j.cell.2013.02.035Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359(15): 1577-89. DOI: 10.1056/ NEJMoa0806470Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359(15): 1577-89. DOI: 10.1056/ NEJMoa0806470Anfossi G, Russo I, Bonomo K, et al. The cardiovascular effects of metformin: further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus. Curr Vasc Pharmacol 2010; 8(3): 327-37.Anfossi G, Russo I, Bonomo K, et al. The cardiovascular effects of metformin: further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus. Curr Vasc Pharmacol 2010; 8(3): 327-37.Libby G, Donnelly LA, Donnan PT, et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009; 32(9): 1620-5. DOI: 10.2337/dc08-2175Libby G, Donnelly LA, Donnan PT, et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009; 32(9): 1620-5. DOI: 10.2337/dc08-2175Ma SJ, Zheng YX, Zhou PC, et al. Metformin use improves survival of diabetic liver cancer patients: systematic review and meta-analysis. Oncotarget 2016 DOI: 10.18632/oncotarget.11033Ma SJ, Zheng YX, Zhou PC, et al. Metformin use improves survival of diabetic liver cancer patients: systematic review and meta-analysis. Oncotarget 2016 DOI: 10.18632/oncotarget.11033Rokkas T, Portincasa P. Colon neoplasia in patients with type 2 diabetes on metformin: A meta-analysis. Eur J Intern Med 2016; 33: 60-6. DOI: 10.1016/j.ejim.2016.05.027Rokkas T, Portincasa P. Colon neoplasia in patients with type 2 diabetes on metformin: A meta-analysis. Eur J Intern Med 2016; 33: 60-6. DOI: 10.1016/j.ejim.2016.05.027Anisimov VN, Bartke A. The key role of growth hormone-insulin-IGF-1 signaling in aging and cancer. Crit Rev Oncol Hematol 2013; 87(3): 201-23. DOI: 10.1016/j. critrevonc.2013.01.005Anisimov VN, Bartke A. The key role of growth hormone-insulin-IGF-1 signaling in aging and cancer. Crit Rev Oncol Hematol 2013; 87(3): 201-23. DOI: 10.1016/j. critrevonc.2013.01.005Karnevi E, Said K, Andersson R, et al. Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells. BMC Cancer 2013; 13: 235. DOI: 10.1186/1471-2407-13-235Karnevi E, Said K, Andersson R, et al. Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells. BMC Cancer 2013; 13: 235. DOI: 10.1186/1471-2407-13-235Quinn BJ, Dallos M, Kitagawa H, et al. Inhibition of lung tumorigenesis by metformin is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling. Cancer Prev Res (Phila) 2013; 6(8): 801-10. DOI: 10.1158/1940-6207. CAPR-13-0058-TQuinn BJ, Dallos M, Kitagawa H, et al. Inhibition of lung tumorigenesis by metformin is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling. Cancer Prev Res (Phila) 2013; 6(8): 801-10. DOI: 10.1158/1940-6207. CAPR-13-0058-TMuzumdar RH, Huffman DM, Atzmon G, et al. Humanin: a novel central regulator of peripheral insulin action. PLoS One 2009; 4(7): e6334. DOI: 10.1371/journal. pone.0006334Muzumdar RH, Huffman DM, Atzmon G, et al. Humanin: a novel central regulator of peripheral insulin action. PLoS One 2009; 4(7): e6334. DOI: 10.1371/journal. pone.0006334Richmond RL, Law J, Kay-Lambkin F. Physical, mental, and cognitive function in a convenience sample of centenarians in Australia. J Am Geriatr Soc 2011; 59(6): 1080-6. DOI: 10.1111/j.1532-5415.2011.03404.xRichmond RL, Law J, Kay-Lambkin F. Physical, mental, and cognitive function in a convenience sample of centenarians in Australia. J Am Geriatr Soc 2011; 59(6): 1080-6. DOI: 10.1111/j.1532-5415.2011.03404.xAndersen-Ranberg K, Schroll M, Jeune B. Healthy centenarians do not exist, but autonomous centenarians do: a population-based study of morbidity among Danish centenarians. J Am Geriatr Soc 2001; 49(7): 900-8.Andersen-Ranberg K, Schroll M, Jeune B. Healthy centenarians do not exist, but autonomous centenarians do: a population-based study of morbidity among Danish centenarians. J Am Geriatr Soc 2001; 49(7): 900-8.Inagaki H, Gondo Y, Hirose N, et al. Cognitive function in Japanese centenarians according to the Mini-Mental State Examination. Dement Geriatr Cogn Disord 2009; 28(1): 6-12. DOI: 10.1159/000228713Inagaki H, Gondo Y, Hirose N, et al. Cognitive function in Japanese centenarians according to the Mini-Mental State Examination. Dement Geriatr Cogn Disord 2009; 28(1): 6-12. DOI: 10.1159/000228713Silver MH, Jilinskaia E, Perls TT. Cognitive functional status of age-confirmed centenarians in a population-based study. J Gerontol B Psychol Sci Soc Sci 2001; 56(3): P134-40.Silver MH, Jilinskaia E, Perls TT. Cognitive functional status of age-confirmed centenarians in a population-based study. J Gerontol B Psychol Sci Soc Sci 2001; 56(3): P134-40.Poon LW, Martin P, Bishop A, et al. Understanding centenarians’ psychosocial dynamics and their contributions to health and quality of life. Curr Gerontol Geriatr Res 2010 DOI: 10.1155/2010/680657Poon LW, Martin P, Bishop A, et al. Understanding centenarians’ psychosocial dynamics and their contributions to health and quality of life. Curr Gerontol Geriatr Res 2010 DOI: 10.1155/2010/680657Jopp D, Rott C. Adaptation in very old age: exploring the role of resources, beliefs, and attitudes for centenarians’ happiness. Psychol Aging 2006; 21(2): 266-80. DOI: 10.1037/0882-7974.21.2.266Jopp D, Rott C. Adaptation in very old age: exploring the role of resources, beliefs, and attitudes for centenarians’ happiness. Psychol Aging 2006; 21(2): 266-80. DOI: 10.1037/0882-7974.21.2.266Kato K, Zweig R, Schechter CB, et al. Positive attitude toward life, emotional expression, self-rated health, and depressive symptoms among centenarians and near-centenarians. Aging Ment Health 2016; 20(9): 930-9. DOI: 10.1080/13607863.2015.1056770Kato K, Zweig R, Schechter CB, et al. Positive attitude toward life, emotional expression, self-rated health, and depressive symptoms among centenarians and near-centenarians. Aging Ment Health 2016; 20(9): 930-9. DOI: 10.1080/13607863.2015.1056770

The authors declare that there are no conflicts of interest present.